Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity

Charles A. Schiffer, Jorge E. Cortes, Andreas Hochhaus, Giuseppe Saglio, Philipp Le Coutre, Kimmo Porkka, Satu Mustjoki, Hesham Mohamed, Neil P. Shah

Research output: Contribution to journalArticle

28 Scopus citations

Abstract

BACKGROUND The proliferation of clonal cytotoxic T-cells or natural killer cells has been observed after dasatinib treatment in small studies of patients with chronic myeloid leukemia (CML). METHODS The incidence of lymphocytosis and its association with response, survival, and side effects were assessed in patients from 3 large clinical trials. Overall, 1402 dasatinib-treated patients with newly diagnosed CML in chronic phase (CML-CP), CML-CP refractory/intolerant to imatinib, or with CML in accelerated or myeloid-blast phase were analyzed. RESULTS Lymphocytosis developed in 32% to 35% of patients and persisted for >12 months. This was not observed in the patients who received treatment with imatinib. Dasatinib-treated patients in all stages of CML who developed lymphocytosis were more likely to achieve a complete cytogenetic response, and patients who had CML-CP with lymphocytosis were more likely to achieve major and deep molecular responses. Progression-free and overall survival rates were significantly longer in patients with CML-CP who were refractory to or intolerant of imatinib and had lymphocytosis. Pleural effusions developed more commonly in patients with lymphocytosis. CONCLUSIONS Overall, lymphocytosis occurred and persisted in many dasatinib-treated patients in all phases of CML. Its presence was associated with higher response rates, significantly longer response durations, and increased overall survival, suggesting an immunomodulatory effect. Prospective studies are warranted to characterize the functional activity of these cells and to assess whether an immunologic effect against CML is detectable.

Original languageEnglish (US)
Pages (from-to)1398-1407
Number of pages10
JournalCancer
Volume122
Issue number9
DOIs
StatePublished - May 1 2016
Externally publishedYes

Keywords

  • T-lymphocytes
  • chronic myeloid
  • dasatinib
  • killer cells
  • leukemia
  • lymphocytosis
  • natural

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity'. Together they form a unique fingerprint.

  • Cite this

    Schiffer, C. A., Cortes, J. E., Hochhaus, A., Saglio, G., Le Coutre, P., Porkka, K., Mustjoki, S., Mohamed, H., & Shah, N. P. (2016). Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer, 122(9), 1398-1407. https://doi.org/10.1002/cncr.29933